Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. In addition, mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are explored before a discussion of potential future trends. This comprehensive coverage of the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors makes Third Generation EGFR Inhibitors a crucial resource for medicinal chemists, drug developers, and researchers investigating cancer therapeutics. Includes full synthetic schemes of all approved and in-trial third generation inhibitors Highlights the emergence of fourth generation EGFR inhibitors and the possibilities of them overcoming constraints of third generation compounds Provides a structural correlation of third and fourth generation EGFR inhibitors, reviewing both their design strategies and typical anticancer activity

Produk Detail:

  • Author : Harun M. Patel
  • Publisher : Elsevier
  • Pages : 208 pages
  • ISBN : 0081026625
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKThird Generation EGFR Inhibitors

Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors
  • Author : Harun M. Patel,Rahul Pawara,Sanjay J. Surana
  • Publisher : Elsevier
  • Release : 27 November 2018
GET THIS BOOKThird Generation EGFR Inhibitors

Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the

Third-Generation EGFR Inhibitors

Third-Generation EGFR Inhibitors
  • Author : Harun M. Patel,Rahul Pawara,S. J. Surana
  • Publisher : Elsevier
  • Release : 15 March 2019
GET THIS BOOKThird-Generation EGFR Inhibitors

EGFR inhibitors are useful tools in cancer therapeutics, but resistance to the first generations have significantly increased, meaning a new generation of improved inhibitors are needed with better efficacy and lower toxicity. Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the

Kinase Drug Discovery

Kinase Drug Discovery
  • Author : Richard A Ward,Frederick W Goldberg
  • Publisher : Royal Society of Chemistry
  • Release : 31 October 2018
GET THIS BOOKKinase Drug Discovery

Kinase inhibition remains an area of significant interest, and growing importance, across academia and the pharmaceutical industry. There are now many marketed drugs that target kinases and a significant number of compounds are currently in various stages of clinical development. This book is a forward-looking analysis of a number of key areas for kinase inhibition in the coming years and builds on the first volume. This includes topics such as screening approaches to target kinases along with different modes of

Resistance to Tyrosine Kinase Inhibitors

Resistance to Tyrosine Kinase Inhibitors
  • Author : Daniele Focosi
  • Publisher : Springer
  • Release : 07 November 2016
GET THIS BOOKResistance to Tyrosine Kinase Inhibitors

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs

Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs
  • Author : Umberto Malapelle,Pierlorenzo Pallante
  • Publisher : Frontiers Media SA
  • Release : 29 August 2017
GET THIS BOOKSecond Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a minor part of lung cancer patients harbouring specific mutations. In the so called wild type population, the first line options bring the median overall survival to go beyond 1 year, and

Tyrosine Kinases as Druggable Targets in Cancer

Tyrosine Kinases as Druggable Targets in Cancer
  • Author : Huan Ren
  • Publisher : BoD – Books on Demand
  • Release : 25 September 2019
GET THIS BOOKTyrosine Kinases as Druggable Targets in Cancer

Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL in chronic myeloid leukemia (CML), has revolutionized disease management. In this book, we examine a few aspects of PTKs and cancer, considering efficacy, predictive markers to therapeutic response, limitations, and future directions in TKI treatment. In this rapidly evolving

Molecular Pathology of Lung Cancer

Molecular Pathology of Lung Cancer
  • Author : Philip T. Cagle,Timothy Craig Allen,Mary Beth Beasley,Lucian R. Chirieac,Sanja Dacic,Alain C. Borczuk,Keith M. Kerr
  • Publisher : Springer Science & Business Media
  • Release : 14 June 2012
GET THIS BOOKMolecular Pathology of Lung Cancer

As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related

Targeted Therapies for Lung Cancer

Targeted Therapies for Lung Cancer
  • Author : Ravi Salgia
  • Publisher : Springer
  • Release : 26 June 2019
GET THIS BOOKTargeted Therapies for Lung Cancer

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s

Frontiers in Anti-Cancer Drug Discovery: Volume 11

Frontiers in Anti-Cancer Drug Discovery: Volume 11
  • Author : Atta-ur-Rahman ,Muhammad Iqbal Choudhary
  • Publisher : Bentham Science Publishers
  • Release : 01 September 2020
GET THIS BOOKFrontiers in Anti-Cancer Drug Discovery: Volume 11

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The

A Beginner's Guide to Targeted Cancer Treatments

A Beginner's Guide to Targeted Cancer Treatments
  • Author : Elaine Vickers
  • Publisher : John Wiley & Sons
  • Release : 08 May 2018
GET THIS BOOKA Beginner's Guide to Targeted Cancer Treatments

The accessible guide to the principles behind new, more targeted drug treatments for cancer Written for anyone who encounters cancer patients, cancer data or cancer terminology, but have no more than a passing knowledge of cell biology. A Beginner's Guide to Targeted Cancer Treatments provides an understanding of how cancer works and the many new treatments available. Using over 100 original illustrations, this accessible handbook covers the biology and mechanisms behind a huge range of targeted drug treatments, including many new

Mitigation of Cancer Therapy Side-Effects with Light

Mitigation of Cancer Therapy Side-Effects with Light
  • Author : Raj Nair,René-Jean Bensadoun
  • Publisher : Morgan & Claypool Publishers
  • Release : 01 November 2016
GET THIS BOOKMitigation of Cancer Therapy Side-Effects with Light

'Light' from low level laser therapy, through a process called photobiomodulation (PBM), has been in existence in supportive care in cancer, in particular in the management of oral mucositis (OM) in patients undergoing chemotherapy, radiation therapy and haematopoietic stem cell transplantation. In this book the authors attempt to portray the current status of the supportive care interventions that are possible with PBM using low level laser therapy (LLLT) in patients undergoing cancer treatment for solid tumours, harmatological malignancies, and head

Central Nervous System Metastases

Central Nervous System Metastases
  • Author : Manmeet Ahluwalia,Philippe Metellus,Riccardo Soffietti
  • Publisher : Springer Nature
  • Release : 05 November 2019
GET THIS BOOKCentral Nervous System Metastases

This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and

Lung Cancer and Personalized Medicine

Lung Cancer and Personalized Medicine
  • Author : Aamir Ahmad,Shirish Gadgeel
  • Publisher : Springer
  • Release : 14 December 2015
GET THIS BOOKLung Cancer and Personalized Medicine

This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry.

Peptidomics of Cancer-Derived Enzyme Products

Peptidomics of Cancer-Derived Enzyme Products
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 30 October 2017
GET THIS BOOKPeptidomics of Cancer-Derived Enzyme Products

Peptidomics of Cancer-Derived Enzyme Products, Volume 42, the latest in The Enzymes series, is ideal for researchers in biochemistry, molecular and cell biology, pharmacology, and cancer, with this volume featuring high-caliber, thematic articles on the topic of peptidomics of cancer-derived enzyme products. Specific chapters cover Circulating peptidome and tumor-resident proteolysis, Colon tumor secretopeptidome, Chemoenzymatic method for glycomics, Human plasma peptidome for pancreatic cancer, Lipoproteomics and quantitative proteomics, Salivaomics: Protein markers/extracellular RNA/DNA in saliva, and Enzyme-responsive vectors for cancer therapy.